DCGI issues guidelines for pharma giants manufacturing Covid-19 vaccine

The DCGI has said that a COVID-19 vaccine candidate should have at least 50 per cent of efficacy in the Phase-III clinical trial for it to be widely deployed.The document has highlighted that the use of COVID-19 preventive vaccines in pregnancy is an important consideration for vaccination programs

from mint - Science https://ift.tt/3iWT2cf
https://ift.tt/eA8V8J